

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-68. (Cancelled)

69. (Currently amended) An isolated protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:62; and

(b) the amino acid sequence encoded by ~~the~~ a nucleotide sequence fully complementary to SEQ ID NO:63,

wherein said protein elicits an immune response against a protein having the amino acid sequence of SEQ ID NO:62.

70. (Previously Presented) A composition comprising the isolated protein of claim 69.

71. (Currently amended) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:62; and

(b) the amino acid sequence encoded by ~~the~~ a nucleotide sequence fully complementary to SEQ ID NO:63.

72. (Previously Presented) An isolated fragment of at least 6 contiguous amino acids of the isolated polypeptide of claim 71.

73. (Previously Presented) The isolated fragment of claim 72, wherein said fragment elicits an immune response against a protein having the amino acid sequence of SEQ ID NO:62.

74. (Previously Presented) The isolated fragment of claim 72, wherein, when tested in an immunoabsorbent test, said at least 6 contiguous amino acid sequence forms an immunocomplex with an antibody raised against a protein having the amino acid sequence of SEQ ID NO:62.

75. (Previously Presented) The isolated fragment of claim 72, wherein said at least 6 contiguous amino acid sequence induces an immediate or delayed-type hypersensitivity response in an animal previously exposed to a protein having the amino acid sequence of SEQ ID NO:62.

76 - 81. (Canceled)